Cover Image
Market Research Report
Product code 

Electrophoresis Reagents Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Published: | Mordor Intelligence Pvt Ltd | 112 Pages | Delivery time: 2-3 business days


Back to Top
Electrophoresis Reagents Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
Published: January 17, 2022
Mordor Intelligence Pvt Ltd
Content info: 112 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents

The electrophoresis reagents market was valued at USD 981.40 million in 2020, and it is expected to reach USD 1,318.99 million by 2026, registering a CAGR of 5.11% during the forecast period, 2021-2026.

Globally, the outbreak of COVID-19 was an incomparable public health emergency that affected almost every industry. The pandemic has had a positive impact on the market growth because the electrophoresis technique has been used in the development of effective therapies, as it is used to separate DNA, RNA, or protein molecules based on their size in the development of effective therapies for COVID-19.

For instance, as per the National Clinical Trial (NCT) Registry, Elsan is conducting a clinical trial to assess serum inflammation profiles by protein electrophoresis on patients hospitalized for infection due to the SARS-CoV-2 virus. Thus, increasing research and development activities in the development of effective therapies are expected to increase the demand for electrophoresis reagents in the near future.

The major factors driving the electrophoresis reagents market include the increasing funding for genomic and proteomic research, rising prevalence of chronic diseases, increasing collaborations between industry and academics, and technological developments.

According to the World Health Organization (WHO), in 2020, the prevalence of chronic diseases increased by 57%. Additionally, as per the International Diabetes Federation (IDF) 2020, globally, there were around 463 million people with diabetes in 2020 and 88 million people in the Southeast Asian region. In India, there were around 77 million people with diabetes. The prevalence of diabetes in the population was 8.9%.

Furthermore, with the increasing cases of chronic diseases such as diabetes, prompt diagnosis and treatment are in need. This has given rise to electrophoresis that is used in clinical laboratories to quantify the lipoproteins using enzymatic staining of cholesterol and triglycerides for the diagnosis of cardiovascular diseases and other chronic diseases, like diabetes.

Electrophoresis is used in the analysis of lipoproteins and apolipoproteins are essential for the valuation of cardiovascular diseases and monitoring of individuals during treatment. Furthermore, the development of this market is also significantly determined by the expanding research exercises in the fields of proteomics and genomics, changing administrative necessities in the pharmaceutical part, and the developing need to reduce healthcare expenses.

Therefore, factors like rising per capita income and increasing public healthcare expenditure are also expected to promote the growth of the electrophoresis reagents market over the forecast period.

Key Market Trends

The Gel Electrophoresis Segment is Expected to Hold a Major Market Share

The major factors driving the gel electrophoresis segment include low operating and instrument cost, rising applications in the pharmaceutical and biotechnology industries, and the increasing burden of infectious diseases, cancer, and genetic disorders.

There has been increasing use of gel-electrophoresis along with RT-PCR assays for the detection of SARS-CoV-2. For instance, a research article by Wischmann F-J et al., published in 2020, stated that the use of gel-electrophoresis in combination with conventional PCR for test analysis is a feasible approach to make SARS-CoV-2 diagnostics available in the whole world.

Gel electrophoresis is a separation technique and analysis of macromolecules such as RNA, DNA, and proteins and their fragments based on their charge and size. It is used in clinical chemistry to separate proteins and also used in molecular biology and biochemistry to separate a mixed population of RNA and DNA fragments by length, among others.

The prevalence of various chronic diseases such as cancer, neurological diseases, and cardiovascular diseases is increasing across the world. For instance, as per the International Agency for Research, globally, 1 in 5 people develops cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease. In addition, as per Globocan data, in 2020, the number of cancer cases rose to 19.3 million, and 10 million deaths were due to cancer.

Globally, there is a rise in the number of prostate, breast, and cervical cancer cases. The rising incidence of such diseases is increasing the demand for new diagnostic procedures and the development of novel therapeutic medicines, which in turn, is driving the growth of the gel electrophoresis segment. Hence, owing to the above factors, the segment is expected to grow in the coming years.

The Asia-Pacific Region is the Fastest Growing Market and is Expected to Follow the Same Trend Over the Forecast Period

The Asia-Pacific region is expected to be the fastest-growing market. In the emerging economies of China, Japan, and India, there has been an increasing number of research activities going on in academic and research institutions and pharmaceutical and biotechnology companies, and increasing adoption of advanced technology and rising health awareness are some of the key factors contributing to the market growth.

Japanese scientists have developed a new method to identify single virus particles based on changes in electrical current through the electrophoresis process. For instance, in 2020, scientists from Osaka University developed a new method for fast and accurate screening tests in the diagnosis of diseases like COVID-19 and influenza. Thus, increasing research and development activities in the development of new diagnostic approaches based on electrophoresis techniques are expected to drive the demand for reagents.

The high growth is also majorly attributed to the rapidly improving healthcare infrastructure and low labor costs in emerging countries. According to the World Health Organization (WHO) 2018 report, chronic diseases such as cardiovascular, chronic respiratory diseases, diabetes, and cancer were top killers in the Southeast Asian region, claiming an estimated 8.5 million lives each year.

The demand for electrophoresis reagents is expected to surge in the Asia-Pacific market as the increasing application of capillary electrophoresis in microbial detection is driving the electrophoresis reagents market. Increasing complexities in the treatment of diseases such as cancer, genetic diseases, and other health issues is also one of the factors fueling the growth of the market.

Furthermore, the application of capillary electrophoresis in areas such as microbial detection and protein analysis is boosting the popularity of capillary electrophoresis and driving the market. Thus, owing to the above factors, the market is expected to grow rapidly in the coming years.

Competitive Landscape

The electrophoresis reagents market is moderately fragmented and competitive. The major players are found adopting various strategies, such as agreements, expansion, contracts, partnerships, new reagent developments, joint ventures, and mergers and acquisitions, to strengthen their positions in the market. Some of the companies currently dominating the market are Agilent Technologies Inc., BioAtlas, Bio-Rad Laboratories Inc., Cytiva, Lonza Group AG, Merck KGaA, Qiagen NV, Sigma-Aldrich Corporation, Takara Bio Inc., and Thermo Fisher Scientific.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Product Code: 62785



  • 1.1 Study Assumptions
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Funding for Genomic and Proteomic Research
    • 4.2.2 Rising Prevalence of Chronic Diseases
    • 4.2.3 Technological Developments
  • 4.3 Market Restraints
    • 4.3.1 Time-consuming Operations
    • 4.3.2 Presence of Alternative Technologies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Product
    • 5.1.1 Gels
      • Agarose Gels
      • Polyacrylamide Gels
      • Starch Gels
    • 5.1.2 Dyes
      • Ethidium Bromide (ETBR) Dyes
      • Bromophenol Blue
      • Sybr Dyes
      • Other Dyes
    • 5.1.3 Buffers
      • Tris/Acetate/EDTA
      • Tris/Borate/EDTA
      • Other Buffers
    • 5.1.4 Other Products
  • 5.2 By Technique
    • 5.2.1 Gel Electrophoresis
    • 5.2.2 Capillary Electrophoresis
  • 5.3 By End User
    • 5.3.1 Academic and Research Institutions
    • 5.3.2 Pharmaceutical and Biotechnology Companies
    • 5.3.3 Laboratories
    • 5.3.4 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • United States
      • Canada
      • Mexico
    • 5.4.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.4.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • GCC
      • South Africa
      • Rest of Middle-East and Africa
    • 5.4.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Agilent Technologies Inc.
    • 6.1.2 BioAtlas
    • 6.1.3 Bio-Rad Laboratories Inc.
    • 6.1.4 Cytiva
    • 6.1.5 Lonza Group AG
    • 6.1.6 Merck KGaA
    • 6.1.7 Qiagen NV
    • 6.1.8 Sigma-Aldrich Corporation
    • 6.1.9 Takara Bio Inc.
    • 6.1.10 Thermo Fisher Scientific
    • 6.1.11 Promega Corporation
    • 6.1.12 Hoefer Inc. (Harvard Bioscience Inc.)
    • 6.1.13 Sebia Group
    • 6.1.14 Randox Laboratories Ltd
    • 6.1.15 Helena Laboratories Corporation